

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

ChemPartner

RRID:SCR_026139

Type: Tool

Proper Citation

ChemPartner (RRID:SCR_026139)

Resource Information

URL: <https://chempartner.com/>

Proper Citation: ChemPartner (RRID:SCR_026139)

Description: Life sciences contract research organization. Provides integrated life science services for drug discovery with expertise in chemistry, biology and pharmacology, DMPK, and exploratory toxicology as well as biologics discovery.

Resource Type: commercial organization, service resource

Keywords: life science services, drug discovery, expertise, chemistry, biology, pharmacology, DMPK, exploratory toxicology, biologics discovery,

Resource Name: ChemPartner

Resource ID: SCR_026139

Record Creation Time: 20241206T053307+0000

Record Last Update: 20260808T190734+0000

Ratings and Alerts

No rating or validation information has been found for ChemPartner.

No alerts have been found for ChemPartner.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Luo L, et al. (2026) CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. Nature communications, 17(1), 619.

Junttila MR, et al. (2026) Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. Cancer research, 86(3), 759.

House NC, et al. (2025) Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer research, 85(7), 1297.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Li X, et al. (2020) Chemical space exploration based on recurrent neural networks: applications in discovering kinase inhibitors. Journal of cheminformatics, 12(1), 42.